Package Leaflet: Information for the User
Tiorfan Infant 4mg/ml Oral Suspension
racecadotril
Read all of this leaflet carefully before your child starts taking this medicine because it contains important information for them.
Contents of the Package Leaflet
Tiorfan Infant 4mg/ml Oral Suspension is a medicine for the treatment of diarrhea.
Tiorfan Infant 4mg/ml Oral Suspension is used in addition to oral rehydration and dietary measures for the treatment of symptoms of acute diarrhea in infants and children over 3 months and weighing 7 kg or more. It should be used together with fluid intake as much as possible and usual dietary measures, when these measures are not sufficient on their own to control diarrhea, and when the cause of diarrhea cannot be treated.
When the cause of diarrhea can be treated, racecadotril may be administered as complementary treatment.
Do not give Tiorfan Infant 4mg/ml Oral Suspension
Warnings and Precautions
Consult your doctor or pharmacist before giving Tiorfan Infant 4mg/ml to your child if:
There have been reports of hypersensitivity/angioedema (swelling) in patients with racecadotril (the active ingredient of this product). Angioedema of the face, extremities, lips, mucous membranes, etc., or swelling of the upper respiratory tract, e.g., tongue, glottis, and/or larynx (throat), may occur. These can occur at any time during therapy. If you experience these side effects, stop treatment immediately and contact your doctor.
Patients with a history of angioedema (swelling) not related to treatment with racecadotril may be at higher risk of angioedema.
The concomitant use of this medicine and others may increase the risk of angioedema (see "Other medicines and Tiorfan Infant 4mg/ml Oral Suspension").
There have been reports of skin reactions with the use of this product. These are usually mild to moderate. When severe skin reactions occur, treatment should be stopped immediately. Do not reintroduce racecadotril.
Be careful with racecadotril:
Severe skin reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported with racecadotril treatment. Suspend the use of racecadotril and seek immediate medical attention if you notice any of the symptoms related to these severe skin reactions described in section 4.
This treatment is given in addition to oral rehydration and dietary measures. Your doctor will decide if your child needs an oral rehydration solution. You will need to follow the conditions of use of the oral rehydration solution prescribed by your doctor and follow the dietary advice.
Other medicines and Tiorfan Infant 4mg/ml Oral Suspension
Tell your doctor or pharmacist if your child is taking, has recently taken, or might take any other medicines, including:
If you have given or have recently given another medicine to your child, including non-prescription medicines, talk to your doctor or pharmacist.
Pregnancy, Breastfeeding, and Fertility
Pregnancy
Consult your doctor or pharmacist before using any medicine.
Based on available data, this medicine is not recommended during pregnancy, at any stage.
Breastfeeding
In the absence of information on the transmission of the active ingredient through breast milk, this medicine should not be used during breastfeeding.
Ask your doctor or pharmacist for advice before taking any medicine.
Driving and Using Machines
This medicine has little or no effect on the ability to drive or use machines.
Tiorfan Infant 4mg/ml Oral Suspension contains sodium, sodium benzoate, sucrose, and propylene glycol
If your doctor has told you that your child has an intolerance to some sugars, ask your doctor before giving Tiorfan Infant 4 mg/ml.
This medicine contains 225 mg of sucrose per dose-kg. This should be taken into account for patients with diabetes mellitus.
Patients with fructose intolerance, glucose-galactose malabsorption syndrome, or sucrose-isomaltase deficiency (rare hereditary diseases) should not take this medicine.
This medicine contains 0.84 mg of sodium (the main component of kitchen/table salt) per dose-kg.
The amount of sodium should be included in the maximum recommended nutritional amount by the WHO, corresponding to 1,500 mg for children.
This medicine contains 1.13 mg of benzoate per dose-kg.
Sodium benzoate may increase the risk of jaundice (yellowing of the skin and eyes) in newborns (up to 4 weeks).
This medicine contains 1.06 mg of propylene glycol per dose-kg.
Always give this medicine to your child exactly as your doctor has told you. You should consult your doctor or pharmacist if you are not sure.
This medicine is an oral suspension with a characteristic strawberry flavor
Only for infants and children between 7 kg and 52 kg.
The recommended dose is based on the child's body weight. It is 1.5 mg/kg/dose (which corresponds to a dose-kg).
Day one: Give a first dose immediately to your child and, depending on the time of the first dose, give up to a maximum of 2 additional doses distributed throughout the day, without exceeding 3 doses in the day. Doses should be administered preferably at the start of the three main meals.
Following days: Give 3 doses distributed throughout the day, preferably at the start of the three main meals.
The maximum daily total dose is 3 doses.
The medicine is administered orally using a syringe (graduated in kg of body weight) that provides a dose of 1.5 mg of racecadotril per graduation point indicated in kg.
For each dose:
Child's weight | Graduation for the first filling of the syringe | Graduation for the second filling of the syringe |
27 kg | 13 kg | 14 kg |
28 kg | 13 kg | 15 kg |
29 kg | 13 kg | 16 kg |
30 kg | 13 kg | 17 kg |
31 kg | 13 kg | 18 kg |
32 kg | 13 kg | 19 kg |
33 kg | 13 kg | 20 kg |
34 kg | 13 kg | 21 kg |
35 kg | 13 kg | 22 kg |
36 kg | 13 kg | 23 kg |
37 kg | 13 kg | 24 kg |
38 kg | 13 kg | 25 kg |
39 kg | 26 kg | 13 kg |
40 kg | 26 kg | 14 kg |
41 kg | 26 kg | 15 kg |
42 kg | 26 kg | 16 kg |
43 kg | 26 kg | 17 kg |
44 kg | 26 kg | 18 kg |
45 kg | 26 kg | 19 kg |
46 kg | 26 kg | 20 kg |
47 kg | 26 kg | 21 kg |
48 kg | 26 kg | 22 kg |
49 kg | 26 kg | 23 kg |
50 kg | 26 kg | 24 kg |
51 kg | 26 kg | 25 kg |
52 kg | 26 kg | 26 kg |
Duration of Treatment
Your doctor will tell you the duration of treatment with Tiorfan Infant 4 mg/mL oral solution. It should be continued until your child has two normal stools, without exceeding 7 days.
Method of Administration
Oral use.
The use of this syringe for oral administration is strictly reserved for the administration of a dose-kg of TIORFAN 4 mg/mL.
To compensate for the loss of fluid due to your child's diarrhea, this medicine should be used together with adequate fluid and electrolyte replacement. The best replacement of fluids and electrolytes is achieved with an oral rehydration solution (consult your doctor or pharmacist if you are not sure).
If you give more Tiorfan Infant 4mg/ml than you should
In case of overdose or accidental ingestion, go immediately to a medical center or consult your doctor, pharmacist, or call the Toxicology Information Service (telephone 91 562 04 20), indicating the medicine and the amount taken.
If you forget to give Tiorfan Infant 4mg/ml
Do not give a double dose to make up for the doses that you have missed giving to your child. Give the next dose.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
You must stop giving Tiorfan Infant 4mg/ml to your child and consult a doctor immediately if your child experiences symptoms of angioedema such as:
Suspend the use of racecadotril and seek immediate medical attention if you notice any of the following symptoms:
Uncommon side effects(reported in at least 1 in 1,000 patients but less than 1 in 100 patients):
Tonsillitis (inflammation of the tonsils), rash (skin rashes), and erythema (redness of the skin)
Frequency not known(cannot be estimated from the available data):
Multiple erythema (pink lesions on the extremities and mouth), tongue edema, lip swelling, eyelid edema, facial edema, facial angioedema (subcutaneous inflammation affecting several parts of the body), hives, nodular erythema (inflammation in the form of a lump under the skin), maculopapular rash (rash with small hard and pustular lesions), pruritus (itching affecting the whole body), prurigo (skin lesions that cause itching).
Reporting of side effects
If your child experiences any type of side effect, consult your doctor or pharmacist, even if it is not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date that appears on the bottle. The expiry date is the last day of the month indicated.
Do not store above 25°C.
Once opened, do not use the contents of this bottle after 10 days.
Do not use this medicine if you notice visible signs of deterioration.
After completing the treatment, return the box, including the oral syringe and the bottle, to your pharmacist so that they can dispose of it properly and appropriately.
Medicines should not be thrown away via wastewater or household waste. Deposit the packaging and medicines that you no longer need in the SIGRE Point of the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines that you no longer need. This way, you will help protect the environment.
Composition of Tiorfan infantil 4mg/ml oral suspension
The active ingredient is racecadotril.
Each ml of oral suspension contains 4 mg of racecadotril.
The other components are:
Sodium benzoate, hydroxyethylcellulose, xanthan gum, sucrose, sodium citrate, lactic acid (for pH adjustment), strawberry flavor (contains propylene glycol). See section 2.
Appearance of the product and packaging contents
This medication is an oral suspension with a characteristic strawberry odor.
Packaging:
PET bottle of 50 ml with child-resistant safety cap and 10 ml graduated syringe in kg. Box of 1.
PET bottle of 180 ml with child-resistant safety cap and 10 ml graduated syringe in kg. Box of 1.
Only some pack sizes may be marketed.
Marketing authorization holder
Bioprojet Pharma
9 RUE RAMEAU
75002 Paris
France
Manufacturer
Unither Liquid Manufacturing
1-3 ALLEE DE LA NESTE
31770 COLOMIERS
FRANCE
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
France: Tiorfan 4 mg/mL Nourrissons et Enfants, suspension buvable.
Belgium: Tiorfix nourrissons et enfants 4 mg/ml suspension buvable. Tiorfix zuigelingen en kinderen 4 mg/ml suspensie voor oraal gebruik. Tiorfix Säuglinge und Kinder 4 mg/ml Suspension zum Einnehmen.
Germany: Tiorfan 4 mg/ml Suspension zum Einnehmen.
Ireland: Hidrasec Infants and Children 4mg/mL Oral Suspension.
Italy: Tiorfan.
Luxembourg: Tiorfix 4 mg/ml nourrissons et enfants, suspension buvable.
Spain: Tiorfan infantil 4 mg/ml oral suspension
Date of last revision of this leaflet:
April 2024
Other sources of information
Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/)
.